News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In
Guide to AI-Enabled Revenue Cycle Management for Molecular Diagnostics and Pathology Practices

Guide to AI-Enabled Revenue Cycle Management for Molecular Diagnostics and Pathology Practices

Dark Daily XiFin White Paper, Guide to AI-Enabled Revenue Cycle Management for Molecular Diagnostics and Pathology Practices

Dark Daily’s free white paper, “Guide to AI-Enabled Revenue Cycle Managment for Molecular Diagnostics and Pathology Practices” is for the laboratory community and has been produced in partnership with XiFin, Inc.  It is available for free download.

In today’s rapidly evolving healthcare landscape, molecular diagnostics and pathology laboratories face increasing challenges in maximizing revenue. Accurately estimating out-of-pocket costs and collecting payments efficiently can be challenging, often leading to delays and patient dissatisfaction. Additionally, ensuring timely and accurate claim submissions is crucial for maximizing revenue, but manual processes can be time-consuming and error-prone.

From complex billing processes to changing payer policies, the traditional revenue cycle management (RCM) approach is no longer sufficient, and maximizing revenue in this complex domain requires a comprehensive and strategic approach. By automating these tasks and streamlining the overall patient journey, healthcare providers can address these key pain points and improve their financial performance.

This white paper serves as a practical guide to enhance the understanding of the POCT team regarding critical success factors and essential functions needed to sustain compliance and produce reliable results. It focuses on the tangible aspects of good laboratory practice and regulatory compliance in routine and urgent patient care settings. This resource will be particularly beneficial to nursing and other clinical staff involved in patient testing.

Click here to download the free white paper. For additional information inquire at info@darkreport.com, or call Amanda Curtis at 512-264-7103.


Produced in partnership with

XIFIN The Power To Do Good

Thermo Fisher Trumped by Merck KGaA’s $7.2 Billion Bid to Acquire Millipore

Clinical Pathology Laboratory Customers of Millipore Not Likely to See Many Changes

It only took a few days for Millipore Corporation (NYSE: MIL) to find a buyer willing to outbid Thermo Fisher Scientific Inc. (NYSE: TMO). Millipore agreed to be acquired by Merck KGaA (FWB: MRK) of Darmstadt, Germany. Merck will pay about $7.2 billion for Millipore, which tops a reported bid of $6 billion made by Thermo Fisher last week.

Because many clinical pathology laboratories use Millipore’s water purification systems and other products, the pending acquisition of Millipore by Merck represents more consolidation among vendors serving the clinical laboratory industry. The acquisition is expected to close during the second half of 2010.
(more…)

Adoption of EMRs Creates Demand for New Healthcare Job of “Scribes”

Clinical pathology laboratories may soon handle lab test orders entered by scribes on behalf of physicians

Along with the growing adoption of electronic medical record (EMR) systems comes robust demand for a new healthcare job: scribes! That is a bit ironic, since many advocates of EMRs believed that physicians would do the primary entry. In fact, the acronym CPOE (computerized physician order entry) was coined to describe this process.

The trend of hiring scribes to interpose between physicians and EMRs is an unanticipated consequence of wider adoption of EMR and EHR (electronic health record) systems. Wider utilization of scribes will directly affect clinical laboratories and pathology groups, because the scribe generally becomes the individual to place orders for clinical laboratory tests at the direction of physicians and track receipt of the lab test results into the EMR.
(more…)

Pathologists Pay Heed! New Spectroscopy Technique May Make Prostate Biopsy Obsolete

Mass General researchers use metabolomic imaging to accurately diagnose tumors

Pathology laboratories may soon find it possible to identify prostate cancer without a biopsy. A new technology under development at Massachusetts General Hospital demonstrates the potential to improve the accuracy of prostate cancer diagnosis. Some studies have demonstrated that nearly a quarter of initial biopsies of the prostate gland may generate false-negative results because the biopsy specimen failed to extract cells from existing cancerous tumors.

To improve the detection of prostate cancer, researchers at Massachusetts General Hospital (MGH) are investigating a new technique that may give doctors a way to locate even small tumors and to provide an accurate determination of a prostate tumor’s prognosis without using a biopsy.

(more…)

Company Brags About “the Largest Pathology Image” of Breast Cancer Tissue

Image is 142,603 by 105,000 pixels in size (or 41.8GB) and was scanned at a 1μm pixel resolution

Is it the largest pathology image ever produced? In an article, the journal BioOptics World reports that a breast tissue image may in fact be the largest digital pathology image ever produced. The image was produced by the TISSUEscope 4000 from Biomedical Photometrics Inc. (BPI) of Waterloo, Ontario, Canada.

The image is available online at http://www.confocal.com/ABOUT/Human_Breast-H&E.html. The announcement of the “largest pathology image ever produced” is a clever way for BPI to call attention to it scanning system. The company describes its product as a high-throughput panoramic scanning system for tissue slides and microarrays that images an area more than 100 times that of an ordinary microscope in a single scan.

(more…)

;